Inreda Diabetic

Executive Summary

Inreda Diabetic is a Dutch private company developing a bi-hormonal fully closed-loop artificial pancreas system (Inreda AP) for type 1 diabetes. The system autonomously delivers insulin and glucagon to maintain glucose levels in the normal range, eliminating the need for manual bolus calculations or meal announcements. Over 100 patients are already using the Inreda AP in real-world settings, and the system has demonstrated superior glycemic control and reduced hypoglycemia in a pivotal study published in The Lancet Digital Health. With strong clinical evidence and a differentiated dual-hormone approach, Inreda is positioned to capture significant market share in the growing artificial pancreas market. The company now aims to scale manufacturing, expand into new European markets, and pursue regulatory approvals in the United States. Success depends on securing commercial partnerships, navigating reimbursement hurdles, and demonstrating long-term safety and efficacy in larger populations. Inreda’s innovative technology addresses key unmet needs in diabetes management, and upcoming catalysts could accelerate its path to widespread adoption.

Upcoming Catalysts (preview)

• Q3 2026Publication of Phase 2/3 trial results in peer-reviewed journal80% success
• Q4 2026CE mark approval for next-generation Inreda AP device70% success
• H2 2026Announcement of strategic partnership with global diabetes company60% success